# US 2022/0008404 A1 · Treatment for severe acute respiratory illness associated with coronavirus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0008404 A1
- Document ID: US20220008404A1
- Status: Published application
- Kind: A1
- Application number: 17/372,129
- Filed: 2021-07-09
- Published: 2022-01-13
- Earliest claimed: 2020-07-10
- Inventors: Sean Downing
- Web page: https://patentgrep.com/patent/US20220008404A1

## CPC

- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61P 31/14: for RNA viruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method is provided for identifying a patient having a respiratory illness and administering to the patient a combination of an anti-inflammatory agent and a leukotriene inhibitor. The method may include treating respiratory illness associated with a coronavirus, and may it may further include reducing or preventing an inflammatory response or cytokine storm for those patients without impairing their immune response against the underlying pathogen.

## Claims

### Claim 1

A method comprising: identifying a patient having a respiratory illness and administering to said patient a combination of an anti-inflammatory agent and a leukotriene inhibitor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the patient has a SARS-CoV-2 infection.

### Claim 3 (depends on 2)

The method of claim 2, wherein the combination of an anti-inflammatory agent and a leukotriene inhibitor is a combination of colchicine and montelukast.

### Claim 4

A method comprising: identifying a patient at risk of developing SARS and administering to said patient a combination of colchicine, montelukast and an NSAID.

### Claim 5 (depends on 2)

The method of claim 2 wherein said colchicine is administered in a total daily dose that is between 0.2 mg to 3 mg per day.

### Claim 6 (depends on 2)

The method of claim 2, wherein said montelukast is administered in a total daily dose that is between 1 mg to 50 mg per day.

### Claim 7 (depends on 4)

The method of claim 4, wherein said NSAID is aspirin that is administered in a total daily dose that is between 600 mg to 4200 mg per day.

### Claim 8

A pharmaceutical composition comprising a combination of an anti-inflammatory agent and a leukotriene inhibitor.

### Claim 9

An oral pharmaceutical composition comprising a combination of an anti-inflammatory agent and a leukotriene inhibitor.

### Claim 10

A pharmaceutical composition comprising a combination of colchicine and montelukast.

### Claim 11 (depends on 10)

The pharmaceutical composition of claim 10 further comprising an NSAID.

### Claim 12 (depends on 11)

The pharmaceutical composition of claim 11, wherein the NSAID is aspirin.
